Abstract: This invention combines artificially expanded genetic information systems (AEGIS) with self-avoiding molecular recognition systems (SAMRS), in processes that involve template-directed primer extension in highly multiplexed form in mixtures containing large numbers of primers. This process yields extension products, or in its PCR format, amplicons, that have AEGIS tags that can be cleanly captured in highly complex mixtures.
Abstract: Systems, including apparatus, methods, compositions, kits, and software, for preparing, reacting, detecting, and/or analyzing samples in droplet-based assay systems, among others. The disclosure emphasizes, but is not limited to, a disposable cartridge with lysis chamber and droplet chamber, particularly for use in droplet-based assays.
Type:
Grant
Filed:
September 30, 2011
Date of Patent:
January 26, 2016
Assignee:
Bio-Rad Laboratories, Inc.
Inventors:
Kevin Dean Ness, Samuel Burd, Benjamin Joseph Hindson, Phillip Belgrader, Billy W. Colston, Jr.
Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.
Abstract: The present invention relates to a method of cloning stable stress tolerant superoxide dismutase from diverse plant species using universal primers.
Type:
Grant
Filed:
March 31, 2009
Date of Patent:
December 15, 2015
Assignee:
Council of Scientific and Industrial Research
Inventors:
Pardeep Kumar Bhardwaj, Arun Kumar, Amit Kishore, Sanjay Ghawana, Arti Rani, Kashmir Singh, Harsharan Singh, Ravi Shankar Singh, Hitesh Kumar, Payal Sood, Som Dutt, Sanjay Kumar, Paramvir Singh Ahuja
Abstract: The invention features compounds of formula (V) or (XII). In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
Type:
Grant
Filed:
January 28, 2011
Date of Patent:
December 1, 2015
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Muthiah Manoharan, Narayanannair K. Jayaprakash, Kallanthottahil G. Rajeev, Michael E. Jung
Abstract: Chips that include one or more particle manipulation mechanisms, or force transduction elements, provided at specific locations to manipulate and localize particles proximal the substrate surface. In one embodiment, individually addressable magnetic control mechanisms such as electric coils are provided at specific locations to create a magnetic field to attract magnetic particles, such a magnetic or magnetizable beads, to those specific locations. In another embodiment, electrostatic control mechanisms such as electrodes are provided to attract and manipulate electrically charged micro-particles. A location may include a crater or well formed in the substrate, or it may include an element on the surface of the substrate. In some embodiments, one or more sensors are located proximal specific locations, e.g., specific craters, so as to analyze specific conditions at each location. In other embodiments, multiple locations share one or more sensors.
Type:
Grant
Filed:
August 15, 2011
Date of Patent:
October 6, 2015
Inventors:
Robert Otillar, David Storek, Christer Johansson
Abstract: The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
September 15, 2015
Assignee:
Arrowhead Research Corporation
Inventors:
Mark Aron Labow, Larry Alexander Gaither, Jason Borawski
Abstract: This invention provides methods for attaching a nucleic acid to a solid surface and for sequencing nucleic acid by detecting the identity of each nucleotide analogue after the nucleotide analogue is incorporated into a growing strand of DNA in a polymerase reaction. The invention also provides nucleotide analogues which comprise unique labels attached to the nucleotide analogue through a cleavable linker, and a cleavable chemical group to cap the —OH group at the 3?-position of the deoxyribose.
Type:
Grant
Filed:
August 5, 2013
Date of Patent:
September 15, 2015
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Jingyue Ju, Zengmin Li, John Robert Edwards, Yasuhiro Itagaki
Abstract: The invention provides systems, devices, methods, and kits for performing an integrated analysis. The integrated analysis can include sample processing, library construction, amplification, and sequencing. The integrated analysis can be performed within one or more modules that are fluidically connected to each other. The one or more modules can be controlled and/or automated by a computer. The integrated analysis can be performed on a tissue sample, a clinical sample, or an environmental sample. The integrated analysis system can have a compact format and return results within a designated period of time.
Abstract: This invention provides a process for sequencing nucleic acids using 3? modified deoxynucleotide analogues or 3? modified deoxyinosine triphosphate analogues, and 3? modified dideoxynucleotide analogues having a detectable marker attached to a base thereof.
Type:
Grant
Filed:
October 17, 2008
Date of Patent:
August 25, 2015
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Jingyue Ju, Dae H. Kim, Jia Guo, Qinglin Meng, Zengmin Li, Huanyan Cao
Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.
Abstract: A capture probe suitable for use with a method for isolating miRNAs. A method for isolating an miRNA of interest from a sample comprising the miRNA of interest comprising providing the capture probe. A method for identifying an miRNA of interest.
Abstract: Artificial transposon sequences having code tags and target nucleic acids containing such sequences. Methods for making artificial transposons and for using their properties to analyze target nucleic acids.
Type:
Grant
Filed:
April 5, 2011
Date of Patent:
July 7, 2015
Assignee:
ILLUMINA, INC.
Inventors:
Frank J. Steemers, Kevin Gunderson, Thomas Royce, Natasha Pignatelli, Igor Yu Goryshin, Nicholas Caruccio
Abstract: The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.
Type:
Grant
Filed:
February 1, 2012
Date of Patent:
May 26, 2015
Assignee:
The Regents of the University of California
Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.
Type:
Grant
Filed:
June 22, 2010
Date of Patent:
May 26, 2015
Assignee:
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH
Inventors:
Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
Abstract: The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
May 19, 2015
Assignee:
DSM IP ASSETS, B.V.
Inventors:
Hendrik Wouter Wisselink, Antonius Jeroen Adriaan Van Maris, Jacobus Thomas Pronk, Paul Klaassen, Rene Marcel De Jong
Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
May 19, 2015
Assignee:
California Institute of Technology
Inventors:
Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin, Irvin S. Y. Chen, Dong Sung An
Abstract: Provided herein is a method for sequencing a polynucleotide molecules. The method includes the steps of providing a plurality of polynucleotide molecules attached to a surface, wherein a first portion of each polynucleotide molecule is attached to a first location of the surface and a second portion of each polynucleotide molecule is attached to a second location of the surface, the relative proximity of the first and second locations being correlated with the probability that the first and second portions are paired, separating the first and second portions of the polynucleotide molecules on the surface, determining the sequences of the first and second portions of the polynucleotide molecules and comparing the relative proximities and the sequences to determine which first and second portions are paired and to determine the sequence of the target polynucleotide molecules.
Type:
Grant
Filed:
August 26, 2011
Date of Patent:
May 12, 2015
Assignee:
Illumina Cambridge Limited
Inventors:
Roberto Rigatti, Niall Anthony Gormley, Jonathan Mark Boutell
Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.
Type:
Grant
Filed:
September 17, 2013
Date of Patent:
May 12, 2015
Assignees:
Board of Regents of the University of Texas System, OTC Technologies, LLC
Inventors:
Kenneth Michael Hargreaves, John Gordon Bruno
Abstract: The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
Type:
Grant
Filed:
August 13, 2010
Date of Patent:
May 12, 2015
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Antonin de Fougerolles, Anna Borodovsky, Tatiana Novobrantseva
Abstract: A dinuclear zinc complex PPi sensor is provided, that may be represented by the formula where X is hydrogen, —COOEt, —CH?CH2, —OR, or —NR2, wherein X is a monovalent organic group having from 1 to about 20 carbon atoms. A method of preparing the dinuclear zinc complex PPi sensor is also provided. Methods for detecting PPi in an aqueous solution and methods for pyrosequencing by using the dinuclear zinc complex are described.
Abstract: A method for constructing a functional nucleic acid molecule comprising 1 or 2 nucleic acid strands, wherein 2 or more fragments having at corresponding ends a functional group pair that can mutually couple through a chemical reaction are introduced into a cell, and a functional nucleic acid molecule comprising 1 or 2 nucleic acid strands is formed by ligating mutually the fragments through a reaction between the functional groups in the cell.
Abstract: The present invention relates to a vector system involving replacement of a Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (WPRE) sequence with an unrelated short spacer sequence for efficient expression of nucleotides of interest in a retroviral vector system and methods of delivering and expressing nucleotides of interest to target cells.
Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.
Abstract: The invention provides improved methods for investigating nucleic acid sequences, wherein at least one additional probe is used which is specific for a (pseudo)gene variant of a target nucleic acid.
Abstract: The present invention relates to the discovery of RNA 5? polyphosphatase enzymes not previously described in the art, methods for discovery of said enzymes, compositions of said enzymes, methods for making said enzymes, and various methods and kits for using said enzymes for biomedical research, for human and non-human diagnostics, for production of therapeutic products, and for other applications. In particular, some embodiments provide compositions, kits and methods for employing RNA polyphosphatases for isolation, purification, production, and assay of capped RNA using a biological sample or a sample from an in vitro capping reaction wherein the sample also contains RNA that is not capped. Other embodiments provide compositions, kits and methods wherein RNA polyphosphatases comprise signal-amplifying enzymes for analyte-specific assays.
Type:
Grant
Filed:
May 4, 2009
Date of Patent:
April 28, 2015
Assignee:
CellScript, LLC
Inventors:
Jerome J. Jendrisak, Ramesh Vaidyanathan, Ronald Meis
Abstract: The present invention is directed to recombinant microalgal cells and their use in production of heterologous hemagglutinin-neuraminidase (HN) polypeptides, as well as compositions and uses thereof.
Abstract: A method of preparing a DNA copy of a target polynucleotide using template switching is described. The method includes mixing a double stranded template/primer substrate made up of a DNA primer oligonucleotide associated with a complementary oligonucleotide template strand with a target polynucleotide in a reaction medium and adding a suitable amount of a non-retroviral reverse transcriptase to the reaction medium to extend the DNA primer oligonucleotide from its 3? end to provide a DNA copy polynucleotide. The DNA copy polynucleotide includes a complementary target DNA polynucleotide that is synthesized using the target polynucleotide as a template. Methods of adding nucleotides to the double stranded template/primer substrate are also described. The method can be used to facilitate detection, PCR amplification, cloning, and determination of RNA and DNA sequences.
Type:
Grant
Filed:
February 23, 2012
Date of Patent:
April 21, 2015
Assignee:
Board of Regents, The University of Texas System
Inventors:
Alan M. Lambowitz, Sabine Mohr, Travis B. White, Scott Kuersten
Abstract: Improved methods that increase the specificity and sensitivity of detection of small RNAs, including miRNAs, using oligonucleotide primers and nucleic acid amplification, are provided. Reaction conditions that result in preferential decrease in cDNA synthesis of RNAs other than the small RNA molecules targeted for detection during miRNA tailing and reverse transcription reactions are described. Using these reaction conditions greater sensitivity and specificity of amplification of small RNAs including miRNAs is achieved.
Abstract: A method for obtaining nucleic acid sequence information that can include steps of (a) providing a first sequencing reagent to a target nucleic acid, wherein the first sequencing reagent comprises at least two different nucleotide monomers, (b) detecting the incorporation of a nucleotide monomer present in the first sequencing reagent into a polynucleotide strand complementary to at least a portion of the target nucleic acid, (c) providing a second sequencing reagent to said target nucleic acid, wherein the second sequencing reagent comprises one or more nucleotide monomers, at least one of the one or more nucleotide monomers being different from the nucleotide monomers present in the first sequencing reagent, and wherein the second sequencing reagent is provided subsequent to providing the first sequencing reagent, and (d) detecting the incorporation of a nucleotide monomer present in the second sequencing reagent into the polynucleotide strand.
Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.
Type:
Grant
Filed:
September 16, 2011
Date of Patent:
April 14, 2015
Assignee:
Cargill, Incorporated
Inventors:
Ellen Burke, Steven John Gort, Paula M. Hicks, Peter Luginbuhl, Sara C. McFarlan, Toby Richardson, Christopher Solheid, David Weiner, Lishan Zhao
Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Abstract: The present invention relates to kits and methods for efficiently generating 5? capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5?-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate, and methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate with detectable dye or enzyme moieties.
Type:
Grant
Filed:
August 28, 2014
Date of Patent:
April 14, 2015
Assignee:
Cellscript, LLC
Inventors:
Jerome Jendrisak, Ronald Meis, Gary Dahl
Abstract: The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties.
Abstract: Improvements in plasmid DNA production technology are needed to insure the economic feasibility of future DNA vaccines and DNA therapeutics. General methods are described, by means of which it is possible to dramatically increase plasmid DNA productivity. These processes feature RNA based inducers of plasmid copy number.
Abstract: Provided is a method for selectively obtaining, for a given target gene, a “joined DNA fragment” wherein just a target gene fragment is joined with desired other DNA fragments, regardless of whether a DNA fragment containing a target gene sequence has been purified. In the provided method, a double-stranded joining DNA fragment containing a sequence A and/or a sequence B is selectively joined to the ends of a target gene fragment. A mixture of a double-stranded gene fragment, the 3? end of which is protruding, and the double-stranded joining DNA fragment, which are related in a prescribed manner, undergoes at least two cycles of thermal denaturation, reassociation, and DNA synthesis, resulting in a “joined DNA fragment,” which is a double-stranded DNA fragment including at least one instance of a sequence resulting from joining sequence A, the target gene sequence, and sequence B. A “single-side joined DNA fragment” can also be obtained, by a similar method.
Type:
Grant
Filed:
September 2, 2010
Date of Patent:
April 7, 2015
Assignee:
National University Corporation University of Toyama
Abstract: Provided herein are systems and methods for nucleotide incorporation reactions. The systems comprise polymerases having altered nucleotide incorporation kinetics and are linked to an energy transfer donor moiety, and nucleotide molecules linked with at least one energy transfer acceptor moiety. The donor and acceptor moieties undergo energy transfer when the polymerase and nucleotide are proximal to each other during nucleotide binding and/or nucleotide incorporation. As the donor and acceptor moieties undergo energy transfer, they generate an energy transfer signal which can be associated with nucleotide binding or incorporation. Detecting a time sequence of the generated signals, or the change in the signals, can be used to determine the order of the incorporated nucleotides, and can therefore be used to deduce the sequence of the target molecule.
Type:
Grant
Filed:
July 30, 2012
Date of Patent:
April 7, 2015
Assignee:
Life Technologies Corporation
Inventors:
Joseph Beechem, Theo Nikiforov, Vi-En Choong, Xinzhan Peng, Guobin Luo, Cheng-Yao Chen, Michael Previte
Abstract: The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).
Type:
Grant
Filed:
December 15, 2006
Date of Patent:
April 7, 2015
Assignee:
University Court of The University of Dundee
Inventors:
William Henry Irwin McLean, Frances Jane Dorothy Smith
Abstract: Nucleic acid molecules encoding chimeric cellulase polypeptides that exhibit improved cellulase activities are disclosed herein. The chimeric cellulase polypeptides encoded by these nucleic acids and methods to produce the cellulases are also described, along with methods of using chimeric cellulases for the conversion of cellulose to sugars such as glucose.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
March 31, 2015
Assignee:
Alliance for Sustainable Energy, LLC
Inventors:
Qi Xu, John O. Baker, Michael E. Himmel
Abstract: Methods are provided for determining whether or not a horse is genetically normal, is a carrier of, or is affected with or predisposed to Congenital Stationary Night Blindness and/or leopard complex spotting. The method is based on detection of an insertion in an intron in the horse Transient Receptor Potential Cation Channel, Subfamily M, Member 1 (TRPM1) gene.
Type:
Grant
Filed:
December 5, 2011
Date of Patent:
March 31, 2015
Assignees:
Cornell University, University of Saskatchewan
Inventors:
Rebecca Bellone, Heather Marie Holl, Samantha Ann Brooks, George Forsyth
Abstract: A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
March 31, 2015
Assignee:
Illumina, Inc.
Inventors:
Eric H. Kawashima, Laurent Farinelli, Pascal Mayer
Abstract: The present disclosure relates to new polymethine compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
Type:
Grant
Filed:
July 7, 2014
Date of Patent:
March 31, 2015
Assignee:
Illumina Cambridge Limited
Inventors:
Nikolai Nikolaevich Romanov, Xiaohai Liu
Abstract: A thermal cycle system and method suitable for mass production of DNA comprising a temperature control body having at least two sectors. Each sector has at least one heater, cooler, or other means for changing temperature. A path traverses the sectors in a cyclical fashion. In use, a piece of tubing or other means for conveying is placed along the path and a reaction mixture is pumped or otherwise moved along the path such that the reaction mixture is repetitively heated or cooled to varying temperatures as the reaction mixture cyclically traverses the sectors. The reaction mixture thereby reacts to form a product. In particular, polymerase chain reaction reactants may continuously be pumped through the tubing to amplify DNA. The temperature control body is preferably a single aluminum cylinder with a grooved channel circling around its exterior surface, and preferably has wedge-shaped or pie-shaped sectors separated by a thermal barrier.
Type:
Grant
Filed:
September 19, 2012
Date of Patent:
March 24, 2015
Assignee:
Marshall University Research Corporation
Inventors:
Derek A. Gregg, Elizabeth E. Murray, Michael L. Norton, Justin T. Swick, Herbert Tesser
Abstract: The present disclosure provides a method to isolate natural & artificial nucleic acids like deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide nucleic acid (PNA) from a solid or liquid sample using cotton. The cotton packed is such that, a solution containing nucleic acids passes through it and the nucleic acids in solution are bound to the cotton in a medium optimal for binding. The nucleic acids are bound to cotton in such a way that, the bound nucleic acids can withstand multiple washes with liquid comprising water and gets eluted in an aqueous buffer, with which eluted nucleic acids can be directly used for amplification using PCR or for any other biochemical or molecular biology needs.
Abstract: Methods of detecting two or more nucleic acids in a multiplex branched-chain DNA assay are provided. Different nucleic acids are captured through cooperative hybridization events on different, identifiable subsets of particles or at different selected positions on a spatially addressable solid support. Compositions, kits, and systems related to the methods are also described.
Abstract: This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created.
Abstract: The present invention provides compositions, methods and kits for use in the detection of small RNA sequences, which allow for rapid and robust amplification and detection. The methods provide improved sensitivity and efficiency in the amplification-based detection of small RNA sequences by incorporating one or more base-modified duplex-stabilizing dNTPs during reverse transcription and/or amplification.